Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent exploratory pain data may point to additional clinical opportunities for the LPA1 receptor antagonist.
Speaking in a session hosted by RBC Capital Markets analyst Nevin Varghese, Stengone discussed a small exploratory Phase 1b study of PIPE-791 in chronic osteoarthritic pain and chronic lower back pain. He said the study enrolled patients across the two pain syndromes, with safety and tolerability as the primary endpoint and exploratory measures including PI-NRS pain scores, responder rates and patient-reported outcomes tied to activities of daily living in osteoarthritis.
